In his new role, Benecchi will lead Sage's global commercial efforts across all Sage programs, new product planning, strategy, and competitive intelligence.
Benecchi will work in collaboration with internal partners to create a shared, mission-driven, launch vision that reflects the input the company receives from external stakeholders.
Among his responsibilities will be to ensure smooth working relationships with Sage's partners and an integrated commercialization plan for zuranolone a once-daily, two-week therapy in Phase 3 clinical development for the treatment of major depressive disorder and postpartum depression.
Benecchi will also lead commercialization strategies across the company's leading portfolio of treatments for brain health disorders.
Chris Benecchi joins Sage from Alexion, where he served as vice president, Global Head of Commercial Excellence.
Previously, he spent eight years at UCB in commercial roles of increasing responsibility including Global Launch Head, Commercial and Medical Affairs, Immunology and Global Commercial Strategy Lead, Immunology.
He began his career in sales at J and J and held sales leadership and senior marketing roles at Takeda as well. Benecchi received an MBA from Duke University and a BA from Colby College.
Sage Therapeutics is a biopharmaceutical company focused on developing novel therapies for patients with debilitating disorders of the brain.
TiumBio files Clinical Trial Application to start Phase 1b TU7710 study
Moderna reports positive interim results from next-generation COVID-19 vaccine trial
Scancell initiates SCOPE trial's iSCIB1+ cohort
Valneva launches Phase 1 trial for next-generation Zika vaccine
argenx obtains VYVGART approval for primary immune thrombocytopenia in Japan
Bio-Thera Solutions' BAT8006 phase II Study receives US FDA IND approval